Synthetic Biology
Home / Services / By Technology / Protein Engineering Services / Protein Modification and Labeling Services / Protein PEGylation / PEGylation Optimization and Characterization Services
Trusted by Leading Research & Pharma Institutions

PEGylation Optimization & Characterization

Advanced bioconjugation services for site-specific PEG modification with comprehensive analytical characterization to accelerate your therapeutic development from concept to clinic.

>95% Selectivity
Full Analytics
4-6 Weeks TAT
Learn More

Trusted by leading research and pharmaceutical institutions

Harvard
Pfizer
MIT
Roche
Stanford
Novartis

Why Choose Us

>95% site selectivity
1-40 kDa PEG range
Complete characterization suite
GMP-compatible available

Site-Specific Conjugation

Engineered amino acids and enzymatic methods

Comprehensive QC

LC-MS, SEC-HPLC, DLS analysis

DoE Optimization

Data-driven process development

Market CAGR
12.5%
Overview Technology Specifications Workflow Applications FAQ
Service Overview

Precision PEGylation for Enhanced Therapeutics

Our PEGylation Optimization & Characterization service combines cutting-edge site-specific conjugation chemistry with comprehensive analytical capabilities to accelerate your therapeutic development.

Site-Specific Conjugation

Achieve >95% site selectivity using engineered amino acids, enzymatic methods, and click chemistry approaches for consistent, reproducible conjugates that preserve therapeutic activity.

  • Engineered cysteine modification
  • Transglutaminase-mediated conjugation
  • Click chemistry PEGylation

Structure-Based Optimization

Leverage protein structure analysis and computational modeling to predict optimal modification sites and maximize therapeutic efficacy while minimizing impact on binding sites.

  • Computational site prediction
  • DoE-driven optimization
  • Predictable pharmacokinetics

Comprehensive Characterization

Full analytical suite including intact mass, peptide mapping, and PEG site determination using advanced LC-MS workflows.

Regulatory Compliance

Complete documentation packages suitable for IND/CTA submissions with GMP-compatible manufacturing options.

Scalable Processes

From milligram to multigram scale with robust processes that ensure batch-to-batch consistency.

Ready to Accelerate Your PEGylated Therapeutic Development?

Get a customized quote for your PEGylation optimization project.

Technology Platform

Advanced PEGylation Technologies

Multiple conjugation strategies to meet your specific protein engineering requirements.

Enzymatic PEGylation

Transglutaminase-mediated conjugation offers exceptional site specificity by targeting defined glutamine residues in flexible protein regions.

>90% Selectivity Mild Conditions

Click Chemistry PEGylation

Copper-catalyzed azide-alkyne cycloaddition (CuAAC) enables rapid, highly efficient conjugation with engineered residues for precise modification.

>95% Efficiency Bioorthogonal

Thiol-Selective Conjugation

Maleimide-PEG reagents provide highly specific modification at cysteine residues under mild conditions for stable thioether linkage.

Chemoselective Fast Kinetics

Quality Control

MS Intact mass analysis by LC-MS
Peptide Peptide mapping for site determination
SEC SEC-HPLC for purity and aggregation
DLS Dynamic light scattering analysis

PEG Options

MW 1-40 kDa molecular weight range
Linear Linear PEG derivatives
Branched Y-shaped and multi-arm options
Cleavable Enzyme-cleavable linkers available
Specifications

Service Specifications

Comprehensive PEGylation services supporting diverse molecular formats and customization options.

Parameter Options Available
PEG Molecular Weight 1 kDa, 2 kDa, 5 kDa, 10 kDa, 20 kDa, 30 kDa, 40 kDa
PEG Architecture Linear, Branched (2-arm, 4-arm), Y-shaped
Protein Size Range 5 kDa - 200 kDa
Site Selectivity >95% with site-specific methods
Modification Site N-terminus, C-terminus, Lysine, Cysteine, Engineered sites
Scale Range Milligram to multigram
Purity Level >90%, >95%, >99% (HPLC purification available)
Quality Standards Research grade, GMP-compatible, cGMP
Workflow

Streamlined PEGylation Process

Our proven workflow ensures quality and efficiency at every stage of your project.

1

Consultation

Project requirements and strategy design

2

Feasibility

Initial trials and condition optimization

3

Scale-Up

Production at target scale

4

Characterization

Comprehensive analytical package

5

Delivery

Documentation and product release

Applications

Therapeutic Applications

PEGylation enhances therapeutic performance across multiple drug modalities.

Cytokines & Interferons

PEGylation of cytokines like interferon-alpha has revolutionized treatment for hepatitis C and other chronic conditions. Our site-specific approaches minimize impact on receptor binding while dramatically extending half-life.

  • Extended circulation half-life from hours to days
  • Reduced dosing frequency
  • Improved patient compliance
  • Enhanced stability in physiological conditions
10-50x
Half-life Extension

Peptide Therapeutics

Peptides like GLP-1 analogs benefit enormously from PEGylation, which protects against enzymatic degradation and reduces rapid renal clearance. Site-specific modification preserves receptor binding affinity.

  • Protection from proteolytic degradation
  • Weekly dosing regimens enabled
  • Maintained receptor binding affinity
  • Improved solubility for hydrophobic sequences
>90%
Activity Retention

Enzyme Replacement Therapies

PEGylated enzymes are used for treating lysosomal storage disorders and other metabolic conditions, with reduced immunogenicity and extended therapeutic window while maintaining catalytic activity.

  • Reduced antigenicity and immunogenicity
  • Extended circulation time
  • Lower infusion frequency
  • Improved tissue penetration
5-40 kDa
PEG Size Range
Testimonials

What Our Partners Say

Trusted by researchers worldwide for quality and reliability.

The site-specific PEGylation service exceeded our expectations. Their team's expertise in enzymatic conjugation helped us achieve a homogeneous product with significantly improved pharmacokinetics.

R
Principal Scientist
Biotechnology Company

Working with their analytical team was seamless. The comprehensive characterization package provided everything we needed for our IND submission, including detailed PEG site mapping.

P
Research Director
Pharmaceutical Company

The DoE-based process optimization saved us months of development time. We achieved our target conversion rates and purity within the first campaign.

L
Lead Researcher
Academic Research Institution
Scientific Literature

Supporting Research

Our platform is backed by peer-reviewed research.

23 Citations

Moving Protein PEGylation from an Art to a Data Science

Mao L, Russell AJ, Carmali S. Bioconjugate Chemistry. 2022.

Data-driven approaches for optimizing PEGylation reaction conditions and site selectivity.

View DOI
156 Citations

From Synthesis to Characterization of Site-Selective PEGylated Proteins

Herrera Belen L, et al. Frontiers in Pharmacology. 2019.

Comprehensive review of site-selective PEGylation methods and analytical characterization techniques.

View DOI
64 Citations

Design and Study of PEG Linkers That Enable Robust Characterization

Saha-Shah A, et al. ACS Pharmacology & Translational Science. 2021.

Cleavable PEG linker design for improved analytical characterization of conjugates.

View DOI
23 Citations

Noncovalent PEGylation of Protein and Peptide Therapeutics

Andrianov AK. Wiley Nanomedicine. 2023.

Alternative PEGylation approaches using noncovalent interactions for dynamic protection.

View DOI
New 2025

PEGylation Technology: Addressing Concerns, Moving Forward

Simberg D, et al. Drug Delivery. 2025.

Addressing PEG immunogenicity concerns and exploring new PEGylation strategies.

View DOI
FAQ

Frequently Asked Questions

What is the difference between random and site-specific PEGylation?
Random PEGylation occurs at multiple reactive sites on the protein surface, creating a mixture of positional isomers with varying biological activity. Site-specific PEGylation targets defined residues, producing homogeneous conjugates with predictable pharmacokinetics. Site-specific methods like enzymatic conjugation or engineered cysteine approaches offer superior batch-to-batch consistency.
How do you determine the optimal PEG size for my therapeutic?
PEG size selection depends on your target indication, dosing route, and desired half-life extension. Smaller PEGs (1-5 kDa) are suitable for peptides and small proteins where minimal steric hindrance is critical. Larger PEGs (10-40 kDa) provide extended half-life for proteins but may impact activity. We work with you to optimize size based on structure-activity relationships.
What characterization methods do you use for PEGylated conjugates?
Our comprehensive characterization suite includes: intact mass analysis by LC-MS, peptide mapping for site determination, SEC-HPLC for purity and aggregation, DLS for hydrodynamic size, and functional assays for bioactivity. We provide complete documentation packages suitable for regulatory submissions.
Can you support GMP manufacturing for clinical trials?
Yes, we offer GMP-compatible and full cGMP manufacturing services for clinical trial material. Our facilities support production from milligram to multigram scales, with complete regulatory documentation packages for IND/CTA submissions.
How long does a typical PEGylation project take?
Standard projects are completed within 4-6 weeks, including feasibility studies and initial characterization. Complex site-specific projects or those requiring extensive optimization may take 6-10 weeks. GMP manufacturing campaigns typically require 3-6 months from project initiation to product release.
Do you offer process development and optimization services?
Absolutely. Our DoE-driven process development identifies critical process parameters and optimizes conjugation conditions for yield, selectivity, and scalability. We provide comprehensive process characterization reports and tech transfer packages.
What PEG reagents do you have available?
We maintain an extensive inventory including: mPEG-NHS esters (1-40 kDa), mPEG-maleimide derivatives, mPEG-aldehyde, mPEG-vinylsulfone, azide/alkyne functionalized PEG, branched PEG reagents (Y-shape, multi-arm), and heterobifunctional PEG linkers.
Can you work with proteins expressed in different systems?
Yes, we work with proteins from various expression systems including E. coli, yeast, insect cells, and mammalian cells. Each system has different characteristics that affect PEGylation strategy, and we adapt our approach accordingly.
How do you handle proteins with multiple reactive sites?
For proteins with multiple reactive sites, we employ site-directed mutagenesis to introduce or remove specific residues, use enzymatic methods with inherent specificity, or engineer the protein to have only one accessible reactive site. We characterize each conjugate to confirm site selectivity.
What is your typical conjugation efficiency?
Our site-specific methods typically achieve >95% conjugation efficiency with >95% site selectivity. Random PEGylation methods may result in mixtures, but our optimization process ensures consistent product profiles. Final purity after purification is typically >95%.

Ready to Start Your Project?

Get a customized quote for your PEGylation Optimization and Characterization Services project. Our experts will respond within 24 hours.

No obligation
24h response
Expert consultation

Recommended Services

· PEGylated Protein Purification Services

Related Resources

· Cost and Efficiency Analysis of CRlSPR-Cas9 Knockout Services in Mice and Cell Lines
· Validating CRISPR Knockouts: Best Practices for qPCR, Sequencing, and Functional Assays
· Step-by-Step Guide to Generating CRISPR Knockout Cell Lines for Research
Quick Links

Home

Products

Services

About Us

Contact Us

Follow Us
CONTACT US

USA

Tel:

Email:

Japan

Tel:

Email:

Korea

Tel:

Email:

Copyright © 2026 CD Biosynsis. All rights reserved.